DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK 1, down from NOK 9. The analyst sees the terms of the rights issue financing as "detrimental to the stock" and also struggles to identify substantial share price catalysts for the next 12- 18 months.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BRRGF: